Victory Capital Management Inc. Sells 254,110 Shares of Haemonetics Corporation (NYSE:HAE)

Victory Capital Management Inc. trimmed its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 93.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,972 shares of the medical instruments supplier's stock after selling 254,110 shares during the quarter. Victory Capital Management Inc.'s holdings in Haemonetics were worth $1,079,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. bought a new stake in Haemonetics during the 4th quarter worth approximately $25,000. Covestor Ltd boosted its stake in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the last quarter. KBC Group NV boosted its stake in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. Vise Technologies Inc. boosted its stake in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares during the last quarter. Finally, CWC Advisors LLC. boosted its stake in shares of Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after purchasing an additional 212 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HAE. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Robert W. Baird began coverage on shares of Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective on the stock. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a research report on Wednesday, July 9th. Finally, Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $97.30.

Haemonetics Stock Up 0.9%

HAE traded up $0.67 during trading on Friday, hitting $74.71. 490,094 shares of the company's stock were exchanged, compared to its average volume of 530,232. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The business's 50 day moving average is $72.88 and its two-hundred day moving average is $67.62. Haemonetics Corporation has a fifty-two week low of $55.30 and a fifty-two week high of $94.99. The stock has a market cap of $3.59 billion, a P/E ratio of 22.57, a PEG ratio of 1.21 and a beta of 0.40.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The firm had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. During the same quarter in the prior year, the company posted $0.90 earnings per share. The business's revenue was down 3.5% on a year-over-year basis. As a group, equities analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.